These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20819492)

  • 1. [Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer].
    Hu M; Kong L; Zhao SQ; Yang GR; Yang WF; Han AQ; Fu Z; Ma L; Zheng JS; Yu JM
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):463-6. PubMed ID: 20819492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
    Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
    Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer.
    Hu M; Xing L; Mu D; Yang W; Yang G; Kong L; Yu J
    Clin Nucl Med; 2013 Aug; 38(8):591-6. PubMed ID: 23797219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J
    Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
    Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
    PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer: Hypoxia changes during chemoradiotherapy and impact on clinical outcome.
    Hu M; Xie P; Lee NY; Li M; Ho F; Lian M; Zhao S; Yang G; Fu Z; Zheng J; Ma L; Yu J
    Medicine (Baltimore); 2019 Oct; 98(40):e17067. PubMed ID: 31577699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
    Minamimoto R; Toyohara J; Seike A; Ito H; Endo H; Morooka M; Nakajima K; Mitsumoto T; Ito K; Okasaki M; Ishiwata K; Kubota K
    J Nucl Med; 2012 Feb; 53(2):199-206. PubMed ID: 22190643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
    Mapelli P; Bettinardi V; Fallanca F; Incerti E; Compierchio A; Rossetti F; Coliva A; Savi A; Doglioni C; Negri G; Gianolli L; Picchio M
    Curr Radiopharm; 2018; 11(1):50-57. PubMed ID: 29119942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
    Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
    Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
    Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
    Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
    Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
    Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
    Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.